Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside
- PMID: 20862451
- DOI: 10.1007/s00134-010-2045-8
Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside
Abstract
Purpose: To delineate some of the characteristics of septic vascular hypotension, to assess the most commonly cited and reported underlying mechanisms of vascular hyporesponsiveness to vasoconstrictors in sepsis, and to briefly outline current therapeutic strategies and possible future approaches.
Methods: Source data were obtained from a PubMed search of the medical literature with the following MeSH terms: Muscle, smooth, vascular/physiopathology; hypotension/etiology; shock/physiopathology; vasodilation/physiology; shock/therapy; vasoconstrictor agents.
Results: Nitric oxide (NO) and peroxynitrite are crucial components implicated in vasoplegia and vascular hyporeactivity. Vascular ATP-sensitive and calcium-activated potassium channels are activated during shock and participate in hypotension. In addition, shock state is characterized by inappropriately low plasma glucocorticoid and vasopressin concentrations, a dysfunction and desensitization of alpha-receptors, and an inactivation of catecholamines by oxidation. Numerous other mechanisms have been individualized in animal models, the great majority of which involve NO: MEK1/2-ERK1/2 pathway, H(2)S, hyperglycemia, and cytoskeleton dysregulation associated with decreased actin expression.
Conclusions: Many therapeutic approaches have proven their efficiency in animal models, especially therapies directed against one particular compound, but have otherwise failed when used in human shock. Nevertheless, high doses of catecholamines, vasopressin and terlipressin, hydrocortisone, activated protein C, and non-specific shock treatment have demonstrated a partial efficiency in reversing sepsis-induced hypotension.
Similar articles
-
Mechanisms of vascular hyporesponsiveness in septic shock.Curr Vasc Pharmacol. 2013 Mar 1;11(2):139-49. Curr Vasc Pharmacol. 2013. PMID: 23506493
-
Vasoplegia in septic shock (review).Georgian Med News. 2015 Feb;(239):56-62. Georgian Med News. 2015. PMID: 25802451 Review.
-
[Indications of vasopressin in the management of septic shock].Ann Fr Anesth Reanim. 2003 Jul;22(7):600-8. doi: 10.1016/s0750-7658(03)00210-7. Ann Fr Anesth Reanim. 2003. PMID: 12946492 Review. French.
-
[Vasopressin and its analogues in the therapy of shock].Cas Lek Cesk. 2004;143(5):307-8, 310-2. Cas Lek Cesk. 2004. PMID: 15305765 Review. Czech.
-
[Pathophysiological mechanisms and treatment of septic shock-induced vasoplegia].Rev Med Suisse. 2011 Dec 14;7(321):2435-8. Rev Med Suisse. 2011. PMID: 22279861 Review. French.
Cited by
-
Autonomic and circulatory alterations persist despite adequate resuscitation in a 5-day sepsis swine experiment.Sci Rep. 2022 Nov 11;12(1):19279. doi: 10.1038/s41598-022-23516-y. Sci Rep. 2022. PMID: 36369521 Free PMC article.
-
Administration of methylene blue in septic shock: pros and cons.Crit Care. 2024 Feb 16;28(1):46. doi: 10.1186/s13054-024-04839-w. Crit Care. 2024. PMID: 38365828 Free PMC article. Review.
-
Methylene blue administration in patients with refractory distributive shock - a retrospective study.Sci Rep. 2020 Feb 4;10(1):1828. doi: 10.1038/s41598-020-58828-4. Sci Rep. 2020. PMID: 32020043 Free PMC article.
-
Outcome of patients with septic shock and high-dose vasopressor therapy.Ann Intensive Care. 2017 Dec;7(1):43. doi: 10.1186/s13613-017-0261-x. Epub 2017 Apr 20. Ann Intensive Care. 2017. PMID: 28425079 Free PMC article.
-
Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study.J Artif Organs. 2017 Sep;20(3):252-259. doi: 10.1007/s10047-017-0967-4. Epub 2017 Jun 6. J Artif Organs. 2017. PMID: 28589286 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous